These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

402 related items for PubMed ID: 19496708

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25. [A case of pulmonary intravascular lymphoma treated with CHOP chemotherapy plus rituximab].
    Ohkubo H, Yoshida T, Ohta K, Takaku T, Katagiri T, Paku J, Kasuga I, Minemura K, Gotoh A, Serizawa H, Mukai K, Ohyashiki K.
    Gan To Kagaku Ryoho; 2005 Apr; 32(4):553-6. PubMed ID: 15853227
    [Abstract] [Full Text] [Related]

  • 26. A phase II trial of rituximab as adjuvant to intensive sequential chemotherapy in patients under 60 years with untreated poor-prognosis diffuse large B-cell lymphoma.
    Coso D, Sebban C, Boulat O, Biron P, Rey J, Aurran T, Chabannon C, Xerri L, Chetaille B, Esterni B, Ivanov V, Stoppa AM, Schiano de Collela JM, Gastaut JA, Maraninchi D, Bouabdallah R.
    Bone Marrow Transplant; 2006 Aug; 38(3):217-22. PubMed ID: 16770316
    [Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28. Rituximab in combination with CHOP chemotherapy for the treatment of diffuse large B cell lymphoma in Chinese patients.
    Li JM, Wang L, Shen Y, Xia ZG, Chen Y, Chen QS, Chen Y, Zeng XY, You JH, Qian Y, Shen ZX.
    Ann Hematol; 2007 Sep; 86(9):639-45. PubMed ID: 17572895
    [Abstract] [Full Text] [Related]

  • 29. Improving outcomes for patients with diffuse large B-cell lymphoma.
    Flowers CR, Sinha R, Vose JM.
    CA Cancer J Clin; 2010 Sep; 60(6):393-408. PubMed ID: 21030533
    [Abstract] [Full Text] [Related]

  • 30. Low absolute lymphocyte count is a poor prognostic marker in patients with diffuse large B-cell lymphoma and suggests patients' survival benefit from rituximab.
    Oki Y, Yamamoto K, Kato H, Kuwatsuka Y, Taji H, Kagami Y, Morishima Y.
    Eur J Haematol; 2008 Dec; 81(6):448-53. PubMed ID: 18691256
    [Abstract] [Full Text] [Related]

  • 31. CHOP and rituximab in elderly patients.
    Portlock CS.
    Curr Oncol Rep; 2002 Sep; 4(5):414. PubMed ID: 12162916
    [No Abstract] [Full Text] [Related]

  • 32. Mutation or polymorphism of the CD20 gene is not associated with the response to R-CHOP in diffuse large B cell lymphoma patients.
    Sar A, Perizzolo M, Stewart D, Mansoor A, Difrancesco LM, Demetrick DJ.
    Leuk Res; 2009 Jun; 33(6):792-7. PubMed ID: 19054557
    [Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34. Reassessment of the prognostic factors of international prognostic index (IPI) in the patients with diffuse large B-cell lymphoma in an era of R-CHOP in Chinese population.
    Yang S, Yu Y, Jun-Min L, Jian-Qing M, Qiu-Sheng C, Yu C, Wei-Li Z, Jian-Hua Y, Hui-Jin Z, Yan W, Li W, Shu C, Zhi-Xiang S.
    Ann Hematol; 2009 Sep; 88(9):863-9. PubMed ID: 19205655
    [Abstract] [Full Text] [Related]

  • 35. [Treatment of diffuse large B-cell lymphoma].
    Gleissner B, Zwick C, Pfreundschuh M.
    Dtsch Med Wochenschr; 2008 Sep; 133(36):1785-94; quiz 1795-6. PubMed ID: 18767006
    [Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37. A phase II study of a THP-COP regimen for the treatment of elderly patients aged 70 years or older with diffuse large B-cell lymphoma.
    Tsurumi H, Hara T, Goto N, Kanemura N, Kasahara S, Sawada M, Yasuda I, Yamada T, Shimizu M, Takami T, Moriwaki H.
    Hematol Oncol; 2007 Sep; 25(3):107-14. PubMed ID: 17457949
    [Abstract] [Full Text] [Related]

  • 38. Intravascular large B-cell lymphoma: remission after rituximab-cyclophosphamide, doxorubicin, vincristine, and prednisolone chemotherapy.
    Horváth B, Demeter J, Eros N, Hársing J, Csomor J, Matolcsy A, Bottlik G, Gyori G, Marschalkó M, Kárpáti S.
    J Am Acad Dermatol; 2009 Nov; 61(5):885-8. PubMed ID: 19632742
    [Abstract] [Full Text] [Related]

  • 39. Intravascular large B-cell lymphoma of the skin: typical clinical manifestations and a favourable response to rituximab-containing therapy.
    Feldmann R, Schierl M, Sittenthaler M, Jahn R, Wogritsch C, Cerroni L, Steiner A, Breier F.
    Dermatology; 2009 Nov; 219(4):344-6. PubMed ID: 19590171
    [Abstract] [Full Text] [Related]

  • 40. Interaction between BCL2 and interleukin-10 gene polymorphisms alter outcomes of diffuse large B-cell lymphoma following rituximab plus CHOP chemotherapy.
    Park YH, Sohn SK, Kim JG, Lee MH, Song HS, Kim MK, Jung JS, Lee JJ, Kim HJ, Kim DH.
    Clin Cancer Res; 2009 Mar 15; 15(6):2107-15. PubMed ID: 19276283
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 21.